[Analysis on dynamic variations of CD4-Positive T-Lymphocytes counts and influencing factors among patients receiving highly active antiretroviral therapy in Guangxi Zhuang autonomous region]

Zhonghua Liu Xing Bing Xue Za Zhi. 2015 Oct;36(10):1125-8.
[Article in Chinese]

Abstract

Objective: To understand dynamic variation of CD4-Positive T-Lymphocytes counts and influencing factors among patients receiving highly active anti-retroviral therapy (HAART) in Guangxi.

Methods: Adult patients who received antiviral treatment for the first time after 1 January 2013 were selected. Their CD4-Positive T-Lymphocytes counts at baseline, 6 months and 12 months after treatment were analyzed. By using the general linear model repeated measures ANOVA, CD4-Positive T-Lymphocytes dynamic variations and influencing factors were described and analyzed.

Results: The average CD4 cell counts of 4 082 patients at baseline, 6(th) months and 12(th) months were (195.3 ± 155.7) cells/mm³, (331.9 ± 202.6) cells/mm³ and (380.9 ± 221.3) cells/mm³, respectively. The time specific differences in CD4-Positive T-Lymphocytes count among them were statistically significant (F=3 161.124, P=0.000). CD4-Positive T-Lymphocytes counts increased over time after treatment. The main influencing factors were sex, age, baseline CD4 cell count, medication, discontinuation of treatment or dose miss. Influenced by sex, age, medication, discontinuation of treatment or dose miss, the increased CD4-Positive T-Lymphocytes count showed a linear trend. Influenced by baseline CD4-Positive T-Lymphocytes counts and dose miss, the increase of CD4-Positive T-Lymphocytes count showed a trend which was conformed to quadratic curvilinear equation.

Conclusion: CD4-Positive T-Lymphocytes counts among patients receiving HAART in Guangxi were influenced by many factors. It is necessary to select the time to start treatment according to patient's characteristics to get good outcome.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Antiretroviral Therapy, Highly Active*
  • CD4 Lymphocyte Count*
  • CD4-Positive T-Lymphocytes
  • China
  • HIV Infections / drug therapy*
  • Humans